SG10201708103RA - Novel α4β7 Peptide Dimer Antagonists - Google Patents

Novel α4β7 Peptide Dimer Antagonists

Info

Publication number
SG10201708103RA
SG10201708103RA SG10201708103RA SG10201708103RA SG10201708103RA SG 10201708103R A SG10201708103R A SG 10201708103RA SG 10201708103R A SG10201708103R A SG 10201708103RA SG 10201708103R A SG10201708103R A SG 10201708103RA SG 10201708103R A SG10201708103R A SG 10201708103RA
Authority
SG
Singapore
Prior art keywords
novel
peptide dimer
antagonists
dimer antagonists
peptide
Prior art date
Application number
SG10201708103RA
Other languages
English (en)
Inventor
Ashok Bhandari
Dinesh V Patel
Larry C Mattheakis
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of SG10201708103RA publication Critical patent/SG10201708103RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
SG10201708103RA 2013-04-02 2014-03-31 Novel α4β7 Peptide Dimer Antagonists SG10201708103RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361807714P 2013-04-02 2013-04-02
US14/229,784 US20140294901A1 (en) 2013-04-02 2014-03-28 Novel a4b7 peptide dimer antagonists

Publications (1)

Publication Number Publication Date
SG10201708103RA true SG10201708103RA (en) 2017-11-29

Family

ID=51621089

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201708103RA SG10201708103RA (en) 2013-04-02 2014-03-31 Novel α4β7 Peptide Dimer Antagonists
SG11201508178UA SG11201508178UA (en) 2013-04-02 2014-03-31 NOVEL α4β7 PEPTIDE DIMER ANTAGONISTS

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201508178UA SG11201508178UA (en) 2013-04-02 2014-03-31 NOVEL α4β7 PEPTIDE DIMER ANTAGONISTS

Country Status (10)

Country Link
US (2) US20140294901A1 (https=)
EP (1) EP2981544B1 (https=)
JP (1) JP6499157B2 (https=)
KR (1) KR20160011625A (https=)
CN (1) CN105339383A (https=)
AU (2) AU2014248321A1 (https=)
CA (1) CA2908593A1 (https=)
HK (1) HK1221233A1 (https=)
SG (2) SG10201708103RA (https=)
WO (1) WO2014165448A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
KR20180100302A (ko) * 2015-10-23 2018-09-10 우니베르지태트 트벤테 인테그린 결합 펩티드 및 그의 용도
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3017926C (en) * 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7534382B2 (ja) 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス, インコーポレイテッド インターロイキン-23受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ.ベー. インターロイキン-23受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
CN114874107B (zh) * 2022-07-12 2022-11-29 中山大学附属第七医院(深圳) 一种氨基脂质及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9613112D0 (en) * 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
US6818617B1 (en) * 1997-08-15 2004-11-16 Temple University- Of The Commonwealth System Of Higher Education EC-3, an inhibitor of α4β1 and α4β7 integrins
AU750175B2 (en) * 1997-11-24 2002-07-11 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
KR100983997B1 (ko) * 2001-01-09 2010-09-28 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
US9193790B2 (en) * 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
WO2009039185A1 (en) * 2007-09-17 2009-03-26 The Trustees Of Columbia University In The City Of New York Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation
JP2011231085A (ja) * 2010-04-30 2011-11-17 Osaka Prefecture Univ 環状ペプチド
EP2444101A1 (en) * 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
US9273093B2 (en) * 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists

Also Published As

Publication number Publication date
KR20160011625A (ko) 2016-02-01
US20190002500A1 (en) 2019-01-03
CA2908593A1 (en) 2014-10-09
JP2016518351A (ja) 2016-06-23
AU2014248321A1 (en) 2015-10-29
EP2981544A4 (en) 2016-12-07
EP2981544B1 (en) 2019-09-04
HK1221233A1 (zh) 2017-05-26
JP6499157B2 (ja) 2019-04-10
CN105339383A (zh) 2016-02-17
WO2014165448A1 (en) 2014-10-09
AU2018220168A1 (en) 2018-09-13
SG11201508178UA (en) 2015-11-27
EP2981544A1 (en) 2016-02-10
US20140294901A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
IL320900A (en) Heterodimer proteins
IL281703A (en) New heterodimeric proteins
SG11201508178UA (en) NOVEL α4β7 PEPTIDE DIMER ANTAGONISTS
SG10201702979SA (en) NOVEL α4β7 PEPTIDE DIMER ANTAGONISTS
IL240606A0 (en) New polypeptides
SG11201602889TA (en) Novel polypeptides
IL242005B (en) A peptide compound
GB201305668D0 (en) Avs6 Integrin Antagonists
GB201311475D0 (en) Polypeptides
EP2981543A4 (en) Novel 4 7 peptide antagonists
HRP20181213T1 (hr) Peptidna smjesa
GB201302597D0 (en) Novel Synthetic Proteins
ZA201506515B (en) Novel sulfonamide trpa1 receptor antagonists
HUP1300139A2 (en) Phenoxypiperidine h3 antagonists
ZA201604490B (en) S1p3 antagonists
ZA201504986B (en) Peptide
PT3061771T (pt) Novo péptido unido a quatro epitopos ctl
ZA201504987B (en) Peptide
GB201309421D0 (en) Polypeptides
PL2983690T3 (pl) Peptydy pochodzące od neuropeptydu Y
ZA201506407B (en) New polypeptides
PL3080276T3 (pl) Polipeptydy toksyczne dla owadów
GB201318941D0 (en) Novel polypeptides
GB201313108D0 (en) Peptide agonist
GB201305465D0 (en) Novel peptides